They promote effective B-cell antibody-mediated immune responses ... There is a growing interest in utilizing these cells to improve therapeutic and vaccination strategies. Several prominent cytokines ...

B cells can control responses of myeloid cells through the release of particular cytokines (small proteins that control the growth and activity of cells in the immune system), disproving the ...

Bispecific antibodies have become component in the arsenal of treatments for hematologic malignancies; management of their side effects is crucial to their success.

A review of the side effects of CAR T-cell therapy, including CRS, ICANS, tumor lysis syndrome, and late-onset toxicities, and management strategies.

No evidence for alteration in B cell cytokine profiles is available Evidence that rituximab affects T-cell activation by B cells includes reduced T-cell expression of HLA-DR, CD154 and CD69 ...

The platform’s first candidate, INB-619, targets CD19, a key marker broadly found on B cells, which play a central role in leukemias, lymphomas, and autoimmune diseases. In preclinical models, INB-619 ...